Nexium I.V. (Esomeprazole)

Esomeprazole selectively and irreversibly inhibits the gastric H+/K+ ATPase (proton pump) in parietal cells, blocking the final step of acid secretion. This leads to a sustained reduction in gastric acidity, allowing mucosal healing and ulcer prevention.

The dose of Nexium I.V. is determined by the prescribing clinician based on the specific indication, severity of the condition, renal and hepatic function, and individual patient factors. Administration is by intravenous infusion as directed by the healthcare professional.

Esomeprazole is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy or lactation only if the potential benefit justifies the potential risk, and the decision should be made by the prescriber.

To order Nexium I.V., submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nexium I.V. (esomeprazole) is the S‑isomer of omeprazole, offering more consistent plasma concentrations and a slightly faster onset of acid suppression compared with many oral PPIs. Intravenous delivery provides rapid therapeutic levels, which can be advantageous in acute care settings where oral administration is not feasible.

Nexium I.V. should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the solution. Once reconstituted, use according to the manufacturer’s stability guidelines and discard any unused portion after the recommended time.

Nexium I.V. is administered by slow intravenous infusion, typically diluted in a compatible IV fluid. The infusion rate and duration are set by the prescribing clinician, who will consider the patient’s condition and any relevant monitoring requirements.

Serious risks include severe allergic reactions such as anaphylaxis, rare skin disorders like Stevens‑Johnson syndrome or toxic epidermal necrolysis, Clostridioides difficile‑associated colitis, and significant electrolyte disturbances such as hypomagnesemia with prolonged use.

Nexium I.V. is contraindicated in patients with known hypersensitivity to esomeprazole, other proton pump inhibitors, or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, and it should be avoided in individuals who have experienced severe adverse reactions to related drugs.